Market Research Logo

Tourette Syndrome - Pipeline Review, H2 2015

Tourette Syndrome - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Tourette Syndrome - Pipeline Review, H2 2015’, provides an overview of the Tourette Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Tourette Syndrome Overview
Therapeutics Development
Pipeline Products for Tourette Syndrome - Overview
Pipeline Products for Tourette Syndrome - Comparative Analysis
Tourette Syndrome - Therapeutics under Development by Companies
Tourette Syndrome - Pipeline Products Glance
Clinical Stage Products
Unknown Stage Products
Tourette Syndrome - Products under Development by Companies
Tourette Syndrome - Companies Involved in Therapeutics Development
AstraZeneca Plc
Catalyst Pharmaceutical Partners, Inc.
Edison Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc.
Psyadon Pharmaceuticals, Inc.
Reviva Pharmaceuticals Inc.
Synchroneuron Inc.
Teva Pharmaceutical Industries Limited
Tourette Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acamprosate calcium SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-5213 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPP-115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dutetrabenazine ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ecopipam hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
valbenazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vatiquinone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vigabatrin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tourette Syndrome - Recent Pipeline Updates
Tourette Syndrome - Dormant Projects
Tourette Syndrome - Discontinued Products
Tourette Syndrome - Product Development Milestones
Featured News & Press Releases
Jan 14, 2015: Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population
Oct 02, 2014: Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
May 28, 2014: Psyadon Announces the Opening of a New Clinical Trial of Ecopipam for the Treatment of Tourette’s Syndrome in Children Ages 7-17
Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome
Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854
May 11, 2011: Tourette Syndrome Association And Psyadon Pharma To Collaborate On Drug Trial For Tourette Syndrome Treatment
Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Tourette Syndrome, H2 2015
Number of Products under Development for Tourette Syndrome - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Tourette Syndrome - Pipeline by AstraZeneca Plc, H2 2015
Tourette Syndrome - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015
Tourette Syndrome - Pipeline by Edison Pharmaceuticals, Inc., H2 2015
Tourette Syndrome - Pipeline by Neurocrine Biosciences, Inc., H2 2015
Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals, Inc., H2 2015
Tourette Syndrome - Pipeline by Reviva Pharmaceuticals Inc., H2 2015
Tourette Syndrome - Pipeline by Synchroneuron Inc., H2 2015
Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Tourette Syndrome Therapeutics - Recent Pipeline Updates, H2 2015
Tourette Syndrome - Dormant Projects, H2 2015
Tourette Syndrome - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Tourette Syndrome, H2 2015
Number of Products under Development for Tourette Syndrome - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report